Rapid and profound radiological and plasma ctDNA responses to dabrafenib plus trametinib in BRAF-mutant papillary craniopharyngioma

Neuro-Oncology Advances 2026 Open access

Read full text
Authors: Santiago Cabezas-Camarero, Rebeca Pérez-Alfayate, Vanesa García-Barberán, Maria Paz De Miguel Novoa, María Elena Gómez del Pulgar, Ignacio Lample Brusel, Isabel Casado-Fariñas, J. Carlos Hernandez, Pedro Pérez-Segura
DOI: 10.1093/noajnl/vdag090
Cited by: 1
References: 23

Abstract

A 38-year-old male patient was diagnosed with a BRAF-V600E mutant papillary craniopharyngioma. Due to the neurological and endocrine sequalae from multiple surgeries, irradiation of residual tumor was disregarded. Dabrafenib plus trametinib treatment was started achieving a rapid neurological improvement and a profound radiological response (-92%), still ongoing 9 months later, despite treatment withdrawal after 7.5 months of therapy due to toxicity (grade 3 pyrexia). In parallel, BRAF-V600E mutation ctDNA monitoring in plasma showed a profound and durable response. Additional therapeutic trials evaluating upfront BRAF-targeted therapy to minimize local therapies (including surgery and radiation) are needed. Liquid biopsy should be further explored as a non-invasive way of diagnosis and treatment monitoring.

Fields of Study & Subjects

Pituitary Gland Disorders and Treatments Glioma Diagnosis and Treatment Head and Neck Surgical Oncology

Publication details

Journal / source
Neuro-Oncology Advances
Publisher
Oxford University Press (OUP)
Volume
8
Issue
1
Pages
vdag090–vdag090
Publication date
1 January 2026
Language
EN